Antibody–Drug Conjugates: Promise & Challenges for Innovation & Investment
3:30 pm - Monday 8th March 2027
- Antibody–drug conjugates are one of oncology’s most promising modalities — delivering potent, targeted therapy more selectively than conventional chemotherapy across the patient journey
- But success is scientifically demanding, depending not on the target alone but on the disciplined integration of biology, engineering and patient selection
- Outlining the critical success factors underpinning ADC development, highlighting how a holistic, end-to-end strategy can maximise clinical efficacy, improve safety, and unlock the full therapeutic potential of next-generation ADCs and making it an attractive investment opportunity
